Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors by E. V. Artamonova, E. I. Kovalenko

Connect to this object online.

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors'... by E. V. Artamonova, E. I. Kovalenko, L. V. Bolotina, M. B. Stenina, R. V. Orlova, M. A. Mukhina

Connect to this object online.

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literat... by N. A. Avxentyev, I. I. Andreyashkina, E. V. Artamonova, L. V. Bolotina, E. I. Kovalenko, N. N. Sisigina

Connect to this object online.

Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review) by Yu. S. Krumin, V. A. Khaylenko, N. A. Kozlov, G. Yu. Cheremis, A. V. Petrovskyy, D. V. Khaylenko, E. V. Artamonova, E. I. Kovalenko

Connect to this object online.

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study by L.  A. Tashireva, N. O. Popova, V. V. Alifanov, V. E.  Goldberg, E. I. Kovalenko, E. V. Artamonova, A. G.  Manikhas, D. M. Ponomarenko, N. V. Levchenko, E. I. Rossokha, S. Yu.  Krasilnikova, M. A. Zafirova, V. M.  Perelmuter

Connect to this object online.